Orphazyme strengthens balance sheet with EUR 9 million financing from Kreos Capital

World News: . []

Anders Fink Vadsholt, CFO of Orphazyme said, “Engaging in this loan facility diversifies our financing strategy and allows us, with only limited dilution, to bolster our cash position as we move closer to significant value inflection points, including the anticipated filing of arimoclomol for NPC in the US and Europe during H1 2020.”   

Aris Constantinides​, General Partner at Kreos, commented, “This is an important time for Orphazyme as the company prepares to file its lead program with regulatory authorities in the US and Europe. We are very pleased to support Orphazyme in its mission to bring innovative new medicines to patients with rare diseases.”  

Anders Vadsholt, CFO                                  +45 28 98 90 55

More news and information about Orphazyme A/S

Published By:

Globe Newswire: 20:14 GMT Tuesday 27th August 2019

Published: .

Search for other references to "orphazyme" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us